HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Feasibility of treating prehypertension with an angiotensin-receptor blocker.

AbstractBACKGROUND:
Prehypertension is considered a precursor of stage 1 hypertension and a predictor of excessive cardiovascular risk. We investigated whether pharmacologic treatment of prehypertension prevents or postpones stage 1 hypertension.
METHODS:
Participants with repeated measurements of systolic pressure of 130 to 139 mm Hg and diastolic pressure of 89 mm Hg or lower, or systolic pressure of 139 mm Hg or lower and diastolic pressure of 85 to 89 mm Hg, were randomly assigned to receive two years of candesartan (Atacand, AstraZeneca) or placebo, followed by two years of placebo for all. When a participant reached the study end point of stage 1 hypertension, treatment with antihypertensive agents was initiated. Both the candesartan group and the placebo group were instructed to make changes in lifestyle to reduce blood pressure throughout the trial.
RESULTS:
A total of 409 participants were randomly assigned to candesartan, and 400 to placebo. Data on 772 participants (391 in the candesartan group and 381 in the placebo group; mean age, 48.5 years; 59.6 percent men) were available for analysis. During the first two years, hypertension developed in 154 participants in the placebo group and 53 of those in the candesartan group (relative risk reduction, 66.3 percent; P<0.001). After four years, hypertension had developed in 240 participants in the placebo group and 208 of those in the candesartan group (relative risk reduction, 15.6 percent; P<0.007). Serious adverse events occurred in 3.5 percent of the participants assigned to candesartan and 5.9 percent of those receiving placebo.
CONCLUSIONS:
Over a period of four years, stage 1 hypertension developed in nearly two thirds of patients with untreated prehypertension (the placebo group). Treatment of prehypertension with candesartan appeared to be well tolerated and reduced the risk of incident hypertension during the study period. Thus, treatment of prehypertension appears to be feasible. (ClinicalTrials.gov number, NCT00227318.).
AuthorsStevo Julius, Shawna D Nesbitt, Brent M Egan, Michael A Weber, Eric L Michelson, Niko Kaciroti, Henry R Black, Richard H Grimm Jr, Franz H Messerli, Suzanne Oparil, M Anthony Schork, Trial of Preventing Hypertension (TROPHY) Study Investigators
JournalThe New England journal of medicine (N Engl J Med) Vol. 354 Issue 16 Pg. 1685-97 (Apr 20 2006) ISSN: 1533-4406 [Electronic] United States
PMID16537662 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial)
CopyrightCopyright 2006 Massachusetts Medical Society.
Chemical References
  • Angiotensin II Type 1 Receptor Blockers
  • Antihypertensive Agents
  • Benzimidazoles
  • Biphenyl Compounds
  • Tetrazoles
  • candesartan cilexetil
Topics
  • Adult
  • Aged
  • Angiotensin II Type 1 Receptor Blockers (adverse effects, pharmacology, therapeutic use)
  • Antihypertensive Agents (adverse effects, pharmacology, therapeutic use)
  • Benzimidazoles (adverse effects, pharmacology, therapeutic use)
  • Biphenyl Compounds (adverse effects, pharmacology, therapeutic use)
  • Blood Pressure (drug effects)
  • Double-Blind Method
  • Dyslipidemias (complications, physiopathology)
  • Feasibility Studies
  • Female
  • Humans
  • Hypertension (epidemiology, prevention & control)
  • Incidence
  • Logistic Models
  • Male
  • Middle Aged
  • Obesity (complications, physiopathology)
  • Tetrazoles (adverse effects, pharmacology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: